219 related articles for article (PubMed ID: 36003398)
21. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
[TBL] [Abstract][Full Text] [Related]
22. Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma.
Beasley GM; Brown MC; Farrow NE; Landa K; Al-Rohil RN; Selim MA; Therien AD; Jung SH; Gao J; Boczkowski D; Holl EK; Salama AKS; Bigner DD; Gromeier M; Nair SK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36175036
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.
Messaoudene M; Périer A; Fregni G; Neves E; Zitvogel L; Cremer I; Chanal J; Sastre-Garau X; Deschamps L; Marinho E; Larousserie F; Maubec E; Avril MF; Caignard A
PLoS One; 2015; 10(7):e0133363. PubMed ID: 26218530
[TBL] [Abstract][Full Text] [Related]
24. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the treatment-naive immune microenvironment in melanoma with
Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
[TBL] [Abstract][Full Text] [Related]
26. Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.
Toker A; Nguyen LT; Stone SC; Yang SYC; Katz SR; Shaw PA; Clarke BA; Ghazarian D; Al-Habeeb A; Easson A; Leong WL; McCready DR; Reedijk M; Guidos CJ; Pugh TJ; Bernardini MQ; Ohashi PS
Clin Cancer Res; 2018 Nov; 24(22):5685-5696. PubMed ID: 30065096
[No Abstract] [Full Text] [Related]
27. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Daud AI; Loo K; Pauli ML; Sanchez-Rodriguez R; Sandoval PM; Taravati K; Tsai K; Nosrati A; Nardo L; Alvarado MD; Algazi AP; Pampaloni MH; Lobach IV; Hwang J; Pierce RH; Gratz IK; Krummel MF; Rosenblum MD
J Clin Invest; 2016 Sep; 126(9):3447-52. PubMed ID: 27525433
[TBL] [Abstract][Full Text] [Related]
28. The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas.
Škuciová V; Drahošová S; Výbohová D; Cígerová V; Adamkov M
Pathol Res Pract; 2020 Sep; 216(9):153071. PubMed ID: 32825944
[TBL] [Abstract][Full Text] [Related]
29. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
30. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
31. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
32. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
[TBL] [Abstract][Full Text] [Related]
33. The Association of CD8+ Cytotoxic T Cells and Granzyme B+ Lymphocytes with Immunosuppressive Factors, Tumor Stage and Prognosis in Cutaneous Melanoma.
Salmi S; Hälinen K; Lin A; Suikkanen S; Jokelainen O; Rahunen E; Siiskonen H; Pasonen-Seppänen S
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551965
[TBL] [Abstract][Full Text] [Related]
34. Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
Sabbatino F; Scognamiglio G; Liguori L; Marra A; Anniciello AM; Polcaro G; Dal Col J; Caputo A; Peluso AL; Botti G; Zeppa P; Ferrone S; Pepe S
Front Immunol; 2020; 11():561390. PubMed ID: 33117345
[TBL] [Abstract][Full Text] [Related]
35. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
36. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
37. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients.
Gide TN; Silva IP; Quek C; Ahmed T; Menzies AM; Carlino MS; Saw RPM; Thompson JF; Batten M; Long GV; Scolyer RA; Wilmott JS
Oncoimmunology; 2020; 9(1):1659093. PubMed ID: 32002281
[TBL] [Abstract][Full Text] [Related]
38. Quantitative multiplex immunohistochemistry reveals inter-patient lymphovascular and immune heterogeneity in primary cutaneous melanoma.
Femel J; Hill C; Illa Bochaca I; Booth JL; Asnaashari TG; Steele MM; Moshiri AS; Do H; Zhong J; Osman I; Leachman SA; Tsujikawa T; White KP; Chang YH; Lund AW
Front Immunol; 2024; 15():1328602. PubMed ID: 38361951
[TBL] [Abstract][Full Text] [Related]
39. Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.
Jacquelot N; Roberti MP; Enot DP; Rusakiewicz S; Semeraro M; Jégou S; Flores C; Chen L; Kwon BS; Borg C; Weide B; Aubin F; Dalle S; Kohrt H; Ayyoub M; Kroemer G; Marabelle A; Cavalcanti A; Eggermont A; Zitvogel L
J Invest Dermatol; 2016 May; 136(5):994-1001. PubMed ID: 26829031
[TBL] [Abstract][Full Text] [Related]
40. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
Inozume T; Hanada K; Wang QJ; Ahmadzadeh M; Wunderlich JR; Rosenberg SA; Yang JC
J Immunother; 2010; 33(9):956-64. PubMed ID: 20948441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
